

Table 3

Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2026



Always use this table in conjunction with **Table 1** and the **Notes** that follow. Medical conditions are often not mutually exclusive. If multiple conditions are present, refer to guidance in all relevant columns. See **Notes** for medical conditions not listed.

Vaccine and other immunizing agents	Pregnancy	Immunocompromised (excluding HIV infection) ^a	HIV infection CD4 percentage and count ^a		CSF leak or cochlear implant	Asplenia or persistent complement component deficiencies	Heart disease or chronic lung disease (CLD)	Kidney failure, End-stage renal disease or on dialysis	Chronic liver disease	Diabetes
			<15% or <200/mm ³	≥15% and ≥200/mm ³						
RSV-mAb (nirsevimab, clesrovimab)		1 dose clesrovimab or nirsevimab during 1 st RSV season depending on maternal RSV vaccination status (See Notes)								
		1 dose nirsevimab 2 nd RSV season (See Notes)					1 dose nirsevimab 2 nd RSV season for CLD (See Notes)			
Hepatitis B										
Rotavirus		SCID ^b								
DTaP/Tdap	DTaP: not applicable Tdap: 1 dose each pregnancy									
Hib		HCT ^c : 3 doses	See Notes			See Notes				
Pneumococcal										
IPV										
COVID-19	*	See Notes								
Influenza inactivated, recombinant		Solid organ transplant: 18 yrs (See Notes)								
LAIV3							Asthma, wheezing: 2–4 years ^d			
MMR	**									
VAR	**									
Hepatitis A										
HPV	**	3-dose series (See Notes)								
MenACWY										
MenB										
RSV (Abrysvo)	Seasonal administration (See Notes)									
Dengue										
Mpox	See Notes									

*For more information, refer to <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care>

- Recommended for all age-eligible children who lack documentation of a complete immunization series
- Not recommended for all children, but recommended for some children based on increased risk for severe outcomes from disease
- Recommended for all age-eligible children, and additional doses may be necessary based on medical condition or other indications. See Notes.
- Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction
- Contraindicated or not recommended. **Vaccinate after pregnancy, if indicated

a. For additional information regarding immunization in immunocompromised children, see <https://publications.aap.org/redbook/book/755/chapter/14074446/Immunization-and-Other-Considerations-in>
 b. Severe combined immunodeficiency
 c. Hematopoietic cell transplantation
 d. LAIV3 contraindicated for children 2–4 years of age with asthma or wheezing during the preceding 12 months